Breakthroughs in Pancreatic Cancer Treatment Offer Hope Amid Ben Sasse's Diagnosis

Former Sen. Ben Sasse (R–Neb.), who previously served as president of the University of Florida, revealed in late December that he had been diagnosed with Stage 4 pancreatic cancer.

"Advanced pancreatic is nasty stuff; it's a death sentence," he observed.

His statement reflects the harsh reality: patients diagnosed at this late stage currently have a five-year survival rate of about 3 percent and often live less than a year.

New Treatments Are Changing the Game

Researchers have recently reported promising advancements in pancreatic cancer treatments that significantly extend life expectancy and, in some cases, even lead to remission.

Daraxonrasib: Targeting the RAS Mutation

Sasse is enrolled in a clinical trial for daraxonrasib, an anti-cancer drug developed by Revolution Medicines. The drug targets a previously hard-to-treat RAS mutation, which drives tumor growth and survival in around 90 percent of pancreatic cancer cases.

In early reports, the company announced that patients taking daraxonrasib doubled their overall survival time, increasing from 6.7 to 13.2 months. Revolution Medicines now plans to seek FDA approval for the treatment.

mRNA Vaccine Shows Promise in Early Trials

Last week, researchers from Memorial Sloan Kettering Cancer Center in New York reported success with a new therapeutic mRNA anti-cancer vaccine. The vaccine works by delivering messenger RNA to cells, instructing them to produce tumor proteins that trigger the immune system to attack cancer cells.

The researchers collaborated with BioNTech and Genentech to develop the vaccine, which targets a version of the RAS cancer-causing mutation. Notably, BioNTech previously partnered with Pfizer to create the highly effective mRNA COVID-19 vaccine.

The team surgically removed pancreatic cancer tumors from 16 early-stage patients (Stage 1 and Stage 2). These tumors were sent to BioNTech, which developed personalized mRNA vaccines targeting the specific mutations in each patient.

In eight of the 16 patients, the vaccine activated cancer-killing immune cells. Of those eight, seven patients were alive four to six years following surgery. Typically, patients who undergo pancreatic cancer surgery live about two and a half years after diagnosis. In contrast, only two of the eight patients whose immune systems did not respond to the vaccine remain alive.

Researchers are now launching a larger Phase 2 clinical trial to further test the vaccine’s efficacy.

mRNA Vaccines and Cancer Immunotherapy: A Potential Synergy

Preliminary research from October 2023 found that receiving mRNA COVID-19 vaccines may prime the immune system to respond more effectively to anti-cancer immunotherapies. Patients who received mRNA COVID-19 vaccines within 100 days of starting cancer immunotherapy showed significant improvements in median and three-year overall survival across various trials.

Debunking Myths About mRNA Vaccines

These encouraging results starkly contrast with unfounded claims that mRNA vaccines are causing an epidemic of "turbo cancers."